Menu
Recruiting NCT06776458

Chronic Impacts of Endocrine Therapy on Cardiovascular and Brain Health Outcomes in Breast Cancer

— Observational Breast Cancer Females

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: N/A - Usual Care.
Who it may be relevant to
Registry conditions: Breast Cancer Females. Basic parameters: No limits · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Canada
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Beyond Cardiotoxicity: Characterizing the Long-term Cardiovascular Side Effects of Breast Cancer Endocrine Treatment

Overview

Aromatase inhibitors are the most used endocrine therapy for hormone-positive breast cancer. Despite the evidence that aromatase inhibitor therapy is associated with increased risk of cardiovascular events, potentially related to the duration of use, no studies have been conducted to characterize the long-term effects of aromatase inhibitor therapy on the heart or vessel structure and function as underlying determinants of cardiovascular mortality. This study will characterize the long-term effects of aromatase inhibitor therapy on established and novel health indices for CVD in breast cancer patients, by examining cross-sectionally compare health indices 1-, 5- and 10-years post-diagnosis in breast cancer survivors to controls. Specifically, our objectives are as follows: 1. To examine the effects of aromatase inhibitor therapy on early risk indicators for cardiovascular disease in the peripheral vasculature and heart, including aortic stiffness (primary outcome) and secondary outcomes of peripheral and carotid artery stiffness, blood biomarkers (lipids), blood pressure, carotid intima media thickness, endothelial function, and left ventricular ejection fraction, global longitudinal strain, and left ventricular diastolic function, in breast cancer survivors compared to controls. 2. To examine the effects of aromatase inhibitor therapy on factors related to cerebrovascular health, autonomic regulation, and cognitive function, including BDNF, heart rate variability, cerebrovascular function in response to a supine-sit-stand maneuver and squatting challenge, and a core battery of cognitive function tests, in breast cancer survivors compared to controls. 3. To examine the effects of aromatase inhibitor therapy on body composition, bone mineral density, and protein metabolism, in breast cancer survivors compared to controls. 4. To examine the effects of aromatase inhibitor therapy on lifestyle factors (behavioural), including diet, physical activity (including cardiorespiratory fitness), sleep, stress, and quality of life, in breast cancer survivors compared to controls. The investigators hypothesize that biologic and behavioural cardiovascular health indices will be deteriorated relative to controls as early as 1 year post-diagnosis and that prolonged use will further accelerate aging-related impairments.

Interventions

  • Other N/A - Usual Care
    Breast cancer survivors will have received usual care aromatase inhibitors for up to 10 years post-diagnosis.

Primary outcome measures

  • Aortic Stiffness [Time frame: Day 2 (In-Person Session)]
Secondary outcome measures (12)
  • Brachial Artery Endothelial Function [Time frame: Day 2 (In-Person Session)]
  • Carotid Artery Stiffness [Time frame: Day 2 (In-Person Session)]
  • Carotid Intima Media Thickness [Time frame: Day 2 (In-Person Session)]
  • Arterial Stiffness [Time frame: Day 2 (In-Person Session)]
  • Left Ventricular Ejection Fraction (LVEF) [Time frame: Day 2 (In-Person Session)]
  • Global Longitudinal Strain [Time frame: Day 2 (In-Person Session)]
  • Left Ventricular Diastolic Function [Time frame: Day 2 (In-Person Session)]
  • Cerebrovascular Response [Time frame: Day 2 (In-Person Session)]
  • Brain derived neurotrophic factor [Time frame: Day 2 (In-Person Session)]
  • Lipid profile [Time frame: Day 2 (In-Person Session)]
  • Hemoglobin A1c [Time frame: Day 2 (In-Person Session)]
  • Insulin resistance [Time frame: Day 2 (In-Person Session)]

Eligibility criteria

Inclusion criteria

Case group:

  • Biologically female
  • Post-menopausal with natural (no bilateral oophorectomy) amenorrhea for at least 1 year
  • If using hormone replacement therapy, limit of a maximum of 3 years of treatment but not within the last 6 months.
  • Diagnosis of stage I, II, or III breast cancer
  • Hormone receptor positive breast cancer
  • HER negative (ER+/PR+/HER-) breast cancer
  • Breast cancer patients \~1 post-diagnosis who have received aromatase inhibitor therapy
  • Breast cancer patients \~5 and \~10 years post-diagnosis who have received aromatase inhibitor therapy for at least 2 years
  • Received surgery/radiation therapies

Control group:

  • Biologically female
  • Post-menopausal with natural (no bilateral oophorectomy) amenorrhea for at least 1 year
  • If using hormone replacement therapy, limit of a maximum of 3 years of treatment but not within the last 6 months.

Exclusion criteria

  • Previous treatment using tamoxifen endocrine therapy in a pre-or peri-menopausal setting
  • Major signs or symptoms of cardiovascular diseases, diabetes, or renal disease (taken from the American College of Sports Medicine's Guidelines for Exercise Testing and Prescription 11th edition Table 2.1: pain or discomfort in the chest, neck, jaw, arms with rest or exercise, shortness of breath at rest or with mild exertion, dizziness or syncope, loss of balance or passing out, ankle edema, palpitations or tachycardia, intermittent claudication, known heart murmur, unusual fatigue with usual activities.)
  • American Heart Association's absolute or relative contraindications for symptom-limited maximal exercise testing (myocardial infarction, aortic or coronary artery stenosis, heart failure, pulmonary embolism or deep vein thrombosis, inflammation of the heart (myocarditis, pericarditis, and/or endocarditis), uncontrolled cardiac arrythmia, advanced or complete electrical heart block, stroke or transient ischemia attack, blood pressure >200mmHg/100mmHg, a cancer diagnosis other than skin cancer)
  • Unable to provide informed consent or communicate in English
  • Mobility limitations to exercise testing (i.e., wheelchair, walker use, limp impeding walking)
  • Extreme claustrophobia

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Case-control

Study locations

Canada · 1 center
  • University of Toronto — Toronto

Identifiers

NCT: NCT06776458 · REB #46819

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗